Abstract
Monoclonal antibodies have shown promising results as a form of cancer immunotherapy used either alone or in combination with another treatment. We model a monoclonal antibody in combination with a dendritic cell (DC) vaccine in order to study treatment optimization. Certain proteins on tumor cells allow the tumor cells to bind to specific receptors on immune cells, rendering the immune cells ineffective. Experiments using mouse models show that a combination of antibodies to these proteins with tumor suppressing drugs improves the effectiveness of cancer vaccines. We create independent models of each of the two treatments in combination with DC therapy, fit them to experimental data, and create a final, data-informed model of the combined treatment. This new model can be used to develop novel therapies involving monoclonal antibodies.
Recommended Citation
Radunskaya, Ami; Kim, Ruby; and Woods II, Timothy
(2018)
"Mathematical Modeling of Tumor Immune Interactions: A Closer Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy,"
Spora: A Journal of Biomathematics: Vol. 4, 25–41.
DOI: http://doi.org/10.30707/SPORA4.1Radunskaya
Available at:
https://ir.library.illinoisstate.edu/spora/vol4/iss1/3
